(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Flying without a Real ID? That'll soon cost you $45, TSA says. - 2Sydney Sweeney is returning in 'The Housemaid's Secret': What to know about 'The Housemaid' sequel
- 3Instructions to Choose the Best Web based Advertising Degree Program for Your Objectives
- 4What do scientists hope to learn from NASA's historic Artemis 2 moon flyby?
- 5Help Your Efficiency with These Work area Updates
- What's changing about healthcare in 2026 — Medicare, Medicaid, ACA, premiums, and enrollment deadlines
- Ukraine: Russians abduct 50 Ukrainians from border village in Sumy
- Best Getaway destination: Ocean side, Mountain, or City
- Electric Vehicles for Eco-Accommodating Driving
- Figure out How to Recognize Early Indications of Depressions
- Blue Origin launches New Glenn rocket on company's first NASA-scale science mission
- Baikonur launch pad damaged after Russian Soyuz launch to International Space Station
- A coup too far: Why Benin's rebel soldiers failed where others in the region succeeded
- Vote in favor of your Favored kind of pasta
